-
-
Overview
-
Specificity: Detects human CD52. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Alemtuzumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
Alemtuzumab biosimilar is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) directed against the 21-28 kD cell surface glycoprotein, CD52, is an IgG1 kappa antibody with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody. The alemtuzumab biosimilar has an approximate molecular weight of 150 kD and is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium.
-
- Properties
- Reference
-
Overview